We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Els3.0
Eyelash Serums (cosmetic) Research
Mostly mechanism / observational
6 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Eyelash Serums (cosmetic) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2012–2026 with a typical study size of 30 participants.
Based on 6 studies · 116 total participants
Confidence
Low confidence
By outcome
Hair & nails
Mostly mechanism / observational6 studies
Safety profile
Too few graded studies2 studies
Vision & eye health
Too few graded studies1 study
Active research area
5 studies in the last 5 years
201220192026
1Observationaln=79 · small study2026
In plain English: About 30% of them contain a prostaglandin analogue. Six prostaglandin analogues were found, including bimatoprost and norbimatoprost.
Couteau C, Coiffard L. · Ann Pharm Fr (2026)
Qualitative survey of 79 marketed cosmetic eyelash-growth serums
In plain English: While non-prostaglandins ingredients show promising data, more studies are needed due to a lack of formal evidence in eyelash serum use.
Baiyasi M, St Claire K, Hengy M, Tur K, Fahs F, Potts G. · J Cosmet Dermatol (2024)
Review splitting serums into prostaglandin-analog and non-prostaglandin categories; only bimatoprost has robust efficacy/safety evidence
Non-prostaglandin ingredients (peptides, panthenol) are 'promising' but formally under-evidenced
US law requires no FDA efficacy or safety assessment before OTC cosmetic lash serums reach consumers
In plain English: These compounds exhibit abnormal reactions such as causing eyelash growth... however, some cases have reported side effects such as pigmentation and dry eyes.
Kim YK, Woo IS, Park CG, Kim A, Choi JD, Son KH, Han KM. · J Chromatogr A (2025)
Glaucoma-drug prostaglandin analogs (bimatoprost, travoprost, tafluprost) are illicitly mixed into eyelash serums sold as cosmetics, which legally cannot contain drugs
Reported side effects of these undeclared analogs include skin/iris pigmentation and dry eyes
A validated LC-MS/MS method was developed to monitor illegal prostaglandin analogs — addressing a regulatory gap
In plain English: Patients using Latisse for its cosmetic enhancement of eyelash length should be warned of this potentially disfiguring side effect, since the cosmetic and ophthalmic preparations are identical.
Sira M, Verity DH, Malhotra R. · Aesthet Surg J (2012)
Case series (n=7): periorbital hollowing from fat atrophy as a side effect of topical prostaglandin-analog (bimatoprost) exposure
These changes can be irreversible and disfiguring
Because covert cosmetic serums share the same prostaglandin-analog active, the same periorbital risk plausibly extends to them
In plain English: The verified analytical method was applied to eyelash serums currently available in the market, and norbimatoprost was detected in one product.
Han KM, Woo IS, Kim YK, Shin EJ, Sung MK, Kim HS, Kim HK. · J Pharm Biomed Anal (2025)
In plain English: At 12 weeks, significant increases were observed in lash length (+8.3%), number (+5%), width (+10.1%), volume (+14.1%), arc (+13.4%), and angle (+28.3%) compared to baseline.